Quadrant Pharmaceuticals Limited, Vesomni 6 mg/0.4 mg modified release tablets defect
Class 4 medicines defect: The MHRA has published a Class 4 medicines defect notification for Vesomni 6 mg/0.4 mg modified release tablets.
Published: 26 March 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 medicines defect notification for Vesomni 6 mg/0.4 mg modified release tablets.
Quadrant Pharmaceuticals Limited have informed the MHRA that their parallel imported packs of Vesomni 6 mg/0.4 mg modified release tablets have been printed with the incorrect barcode/GTIN on the carton.
Further information, advice and details of the affected batches can be found on the MHRA website.